Clinical trial
A DB, Randomized, Placebo-controlled Study of the Tolerability, Efficacy, Safety, and Dose Range of Intramyocardial CLBS14 for Reduction of Angina Episodes in Patients With Refractory Chronic Myocardial Ischemia (ACT34-CMI)
NCT00300053 is registered in ClinicalTrials.gov with Lisata Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A DB, Randomized, Placebo-controlled Study of the Tolerability, Efficacy, Safety, and Dose Range of Intramyocardial CLBS14 for Reduction of Angina Episodes in Patients With Refractory Chronic Myocardial Ischemia (ACT34-CMI)
- Lead sponsor
- Lisata Therapeutics, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 30, 2006
- Completion date
- March 31, 2009
- Enrollment
- 321 (actual)
- Sites
- 26
Conditions
As the registry lists them; a condition with its own page is linked.